PureTech Announces Leadership Transition
The Board of Directors has appointed Robert Lyne as Interim CEO with effect from today. Mr. Lyne joined PureTech as Chief Portfolio Officer in January 2024 and is an experienced leader of UK-listed life science innovation and venture capital companies, having previously served as CEO of Arix Bioscience plc. He will continue to work closely with PureTech's Board and management team as the Company delivers on its strategic objectives.
Sharon Barber-Lui, Interim Chair of PureTech's Board of Directors, said: 'The Board is grateful to Bharatt for his leadership and dedication to the Company over the past eight years. On behalf of the Board, I would like to sincerely thank him for his many contributions and wish him every success in the future. We remain focused on driving shareholder value, and Rob's extensive operational and capital markets experience will be key as he collaborates with the Board and engages with shareholders.'
Robert Lyne, Interim Chief Executive Officer of PureTech, said: 'I am honored to step into the role of Interim CEO and to continue working with this exceptional team at such an exciting time for the Company. PureTech has a high-value portfolio, and I look forward to building on the momentum we've generated as we advance our programs and deliver on meaningful milestones to create value for patients and shareholders.'
Dr. Bharatt Chowrira, said: 'It has been a true privilege to be part of PureTech's journey over the past eight years, including as CEO. I'm incredibly proud of what we've accomplished together—from advancing innovative science to progressing breakthrough clinical programs—and I leave with full confidence in the strength of the team and the exciting opportunities ahead for PureTech.'
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.
For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements that relate to our expectations around our therapeutic candidates and approach towards addressing major diseases, our plans to advance our programs and deliver on our milestones, our future plans, prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
After a stonking set of results, can the Aviva share price continue to power higher?
After years in the doldrums, long-standing shareholders of Aviva (LSE: AV.) finally have something to shout home about, with the share price up 41% in 2025. The transformation over the past few years into a lean, capital-light business has undoubtedly taken the market by surprise. Now that it's finally got rid of the label of being a 'boring' stock, can the growth story continue? Evolving business model At the heart of Aviva's transformation has been a shift toward a capital-light business model. Less than three years ago, over half of all profits were generated from the more capital intensive business units of Retirement and Heritage. Today, the mix is totally different with General Insurance accounting for half of all profits. But the business isn't ending there. By the end of next year, it expects that over 70% of all profits will be generated from the capital-light insurance, wealth, and protection businesses. Driving this optimistic forecast is the Direct Line acquisition, which completed last month. Direct Line Following the buy-out of personal lines insurance competitor Direct Line, the business now boasts greater than 21m UK customers on its books. To put that in perspective, only Lloyds Banking Group is larger. Today, 40% of the adult UK population has a policy of some sort with them. One of the most important aspects for any insurer looking to grow its book is to find innovative way of reaching more customers. Acquiring Direct Line will boost its presence across retail channels (e.g., through price comparison websites) as well as strengthen its position in lower-cost segments. As it deepens its relationships with customers, I foresee a virtuous cycle ensuing. To provide but one example, clear synergies exist between the newly acquired Green Flag brand, Direct Line's Auto Services, and its own in-house car repair service, Solent. Risks One of the key factors that has boosted profits for Aviva over the past few years has been sky-rocketing insurance premiums. However, clear evidence is emerging that this trend is now going into reverse. The latest monthly national general insurance price index shows that motor insurance premiums across the industry have now fallen for seven months in a row. Premiums are now on average 6% lower than at the start of the year. Now, these figures must be treated with caution because they only include data from price comparison websites. Aviva sells a number of policies direct and through intermediation channels too. Another risk I foresee is potential challenges from the integration of Direct Line into its core business. The business foresees cost efficiencies of £125m over the next three years. However, there is no guarantee that these will emerge. Amalgamating two large businesses together is a lot harder than it looks on paper. Many mergers and acquisitions in the past have failed to deliver on expected cost savings. Nevertheless, I think there is an awful lot to like about Aviva. It operates in many high-growth markets including pensions, advice, and investments. With a growing customer base, the opportunities are clearly there. And the icing on the cake is a forward dividend yield of 5.8%. I have been accumulating the stock for years, and after an excellent set of results, expect to buy more soon. The post After a stonking set of results, can the Aviva share price continue to power higher? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Andrew Mackie has positions in Aviva Plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025
Yahoo
29 minutes ago
- Yahoo
Aviva First Half 2025 Earnings: EPS: UK£0.22 (vs UK£0.23 in 1H 2024)
Explore Aviva's Fair Values from the Community and select yours Aviva (LON:AV.) First Half 2025 Results Key Financial Results Revenue: UK£12.4b (up 14% from 1H 2024). Net income: UK£578.0m (down 6.3% from 1H 2024). Profit margin: 4.7% (down from 5.7% in 1H 2024). The decrease in margin was driven by higher expenses. EPS: UK£0.22 (down from UK£0.23 in 1H 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Aviva Earnings Insights Looking ahead, revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Insurance industry in the United Kingdom. Performance of the British Insurance industry. The company's shares are up 3.1% from a week ago. Risk Analysis You should always think about risks. Case in point, we've spotted 2 warning signs for Aviva you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
29 minutes ago
- Yahoo
Secure Trust Bank First Half 2025 Earnings: EPS: UK£0.88 (vs UK£0.67 in 1H 2024)
Explore Secure Trust Bank's Fair Values from the Community and select yours Secure Trust Bank (LON:STB) First Half 2025 Results Key Financial Results Revenue: UK£75.4m (up 11% from 1H 2024). Net income: UK£16.7m (up 31% from 1H 2024). Profit margin: 22% (up from 19% in 1H 2024). EPS: UK£0.88 (up from UK£0.67 in 1H 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Secure Trust Bank Earnings Insights Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Banks industry in the United Kingdom. Performance of the British Banks industry. The company's shares are up 4.1% from a week ago. Risk Analysis You still need to take note of risks, for example - Secure Trust Bank has 2 warning signs we think you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
